Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: a translational study from chronic life stress to brain injury.

Pan H, Steixner-Kumar AA, Seelbach A, Deutsch N, Ronnenberg A, Tapken D, von Ahsen N, Mitjans M, Worthmann H, Trippe R, Klein-Schmidt C, Schopf N, Rentzsch K, Begemann M, Wienands J, Stöcker W, Weissenborn K, Hollmann M, Nave KA, Lühder F, Ehrenreich H.

Mol Psychiatry. 2020 Feb 24. doi: 10.1038/s41380-020-0672-1. [Epub ahead of print]

PMID:
32089545
2.

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.

Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Abraham A, Althaus K, Becks G, Berrouschot J, Berthel J, Bode FJ, Burghaus L, Cangür H, Daffertshofer M, Edelbusch S, Eggers J, Gerlach R, Gröschel K, Große-Dresselhaus F, Günther A, Haase CG, Haensch CA, Harloff A, Heckmann JG, Held V, Hieber M, Kauert A, Kern R, Kerz T, Köhrmann M, Kraft P, Kühnlein P, Latta J, Leinisch E, Lenz A, Leithner C, Neumann-Haefelin T, Mäurer M, Müllges W, Nolte CH, Obermann M, Partowi S, Patzschke P, Poli S, Pulkowski U, Purrucker J, Rehfeldt T, Ringleb PA, Röther J, Rossi R, El-Sabassy H, Sauer O, Schackert G, Schäfer N, Schellinger PD, Schneider A, Schuppner R, Schwab S, Schwarte O, Seitz RJ, Senger S, Shah YP, Sindern E, Sparenberg P, Steiner T, Szabo K, Urbanek C, Sarnowksi BV, Weissenborn K, Wienecke P, Witt K, Wruck R, Wunderlich S.

Int J Stroke. 2020 Jan 19:1747493019895654. doi: 10.1177/1747493019895654. [Epub ahead of print]

PMID:
31955706
3.

Markers of endothelial pathology to support detection of atrial fibrillation in embolic stroke of undetermined source.

Ziegler NL, Sieweke JT, Biber S, Gabriel MM, Schuppner R, Worthmann H, Martens-Lobenhoffer J, Lichtinghagen R, Bode-Böger SM, Bavendiek U, Weissenborn K, Grosse GM.

Sci Rep. 2019 Dec 19;9(1):19424. doi: 10.1038/s41598-019-55943-9.

4.

The Frequency and Timing of Recurrent Stroke.

Stahmeyer JT, Stubenrauch S, Geyer S, Weissenborn K, Eberhard S.

Dtsch Arztebl Int. 2019 Oct 18;116(42):711-717. doi: 10.3238/arztebl.2019.0711.

5.

Impact of immunosuppressive therapy on brain derived cytokines after liver transplantation.

Dirks M, Pflugrad H, Tryc AB, Schrader AK, Ding X, Lanfermann H, Jäckel E, Schrem H, Beneke J, Barg-Hock H, Klempnauer J, Falk CS, Weissenborn K.

Transpl Immunol. 2020 Feb;58:101248. doi: 10.1016/j.trim.2019.101248. Epub 2019 Oct 24.

PMID:
31669260
6.

Quantitative magnetic resonance imaging indicates brain tissue alterations in patients after liver transplantation.

Goede LL, Pflugrad H, Schmitz B, Lanfermann H, Tryc AB, Barg-Hock H, Klempnauer J, Weissenborn K, Ding XQ.

PLoS One. 2019 Sep 25;14(9):e0222934. doi: 10.1371/journal.pone.0222934. eCollection 2019.

7.

ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis.

Putzer AS, Worthmann H, Grosse GM, Goetz F, Martens-Lobenhoffer J, Dirks M, Kielstein JT, Lichtinghagen R, Budde U, Bode-Böger SM, Weissenborn K, Schuppner R.

J Thromb Thrombolysis. 2020 Jan;49(1):67-74. doi: 10.1007/s11239-019-01941-7.

PMID:
31482326
8.

Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation.

Pflugrad H, Tryc AB, Goldbecker A, Barg-Hock H, Strassburg C, Klempnauer J, Lanfermann H, Weissenborn K, Raab P.

PLoS One. 2019 Aug 23;14(8):e0221626. doi: 10.1371/journal.pone.0221626. eCollection 2019.

9.

Hepatic Encephalopathy Is Reversible in the Long Term After Liver Transplantation.

Hopp AE, Dirks M, Petrusch C, Goldbecker A, Tryc AB, Barg-Hock H, Strassburg C, Klempnauer J, Weissenborn K, Pflugrad H.

Liver Transpl. 2019 Nov;25(11):1661-1672. doi: 10.1002/lt.25626. Epub 2019 Sep 20.

PMID:
31437344
10.

Septal total atrial conduction time for prediction of atrial fibrillation in embolic stroke of unknown source: a pilot study.

Sieweke JT, Biber S, Weissenborn K, Heuschmann PU, Akin M, Zauner F, Gabriel MM, Schuppner R, Berliner D, Bauersachs J, Grosse GM, Bavendiek U.

Clin Res Cardiol. 2020 Feb;109(2):205-214. doi: 10.1007/s00392-019-01501-2. Epub 2019 Jun 24.

11.

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.

Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators.

N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959.

PMID:
31091372
12.

Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?

Kornerup LS, Pflugrad H, Weissenborn K, Vilstrup H, Dam G.

Hepat Med. 2019 Mar 18;11:41-46. doi: 10.2147/HMER.S144667. eCollection 2019.

13.

Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.

Schmitz B, Pflugrad H, Tryc AB, Lanfermann H, Jäckel E, Schrem H, Beneke J, Barg-Hock H, Klempnauer J, Weissenborn K, Ding XQ.

Aliment Pharmacol Ther. 2019 Jun;49(11):1431-1441. doi: 10.1111/apt.15256. Epub 2019 Apr 21.

PMID:
31006881
14.

Cellular and Molecular Effects of High-Molecular-Weight Heparin on Matrix Metalloproteinase 9 Expression.

Huber R, Attili/Abedalkhader R, Küper D, Hauke L, Lüns B, Brand K, Weissenborn K, Lichtinghagen R.

Int J Mol Sci. 2019 Mar 30;20(7). pii: E1595. doi: 10.3390/ijms20071595.

15.

Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions.

Weissenborn K.

J Clin Exp Hepatol. 2019 Jan-Feb;9(1):109-111. doi: 10.1016/j.jceh.2018.08.010. Epub 2018 Sep 17. Review.

16.

Plasma Dimethylarginine Levels and Carotid Intima-Media Thickness are related to Atrial Fibrillation in Patients with Embolic Stroke.

Grosse GM, Biber S, Sieweke JT, Martens-Lobenhoffer J, Gabriel MM, Putzer AS, Hasse I, van Gemmeren T, Schuppner R, Worthmann H, Lichtinghagen R, Bode-Böger SM, Bavendiek U, Weissenborn K.

Int J Mol Sci. 2019 Feb 9;20(3). pii: E730. doi: 10.3390/ijms20030730.

17.

Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles.

Weissenborn K.

Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. Review.

18.

Cerebral patterns of neuropsychological disturbances in hepatitis C patients.

Prell T, Dirks M, Arvanitis D, Braun D, Peschel T, Worthmann H, Schuppner R, Raab P, Grosskreutz J, Weissenborn K.

J Neurovirol. 2019 Apr;25(2):229-238. doi: 10.1007/s13365-018-0709-2. Epub 2019 Jan 4.

PMID:
30610739
19.

Cortical networks are disturbed in people with cirrhosis even in the absence of neuropsychometric impairment.

Olesen SS, Jackson CD, Gram M, Zacharias HD, Dirks M, Weissenborn K, Drewes AM, Morgan MY.

Clin Neurophysiol. 2019 Mar;130(3):419-427. doi: 10.1016/j.clinph.2018.11.011. Epub 2018 Nov 26.

PMID:
30552046
20.

Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

Forton D, Weissenborn K, Bondin M, Cacoub P.

Antivir Ther. 2018;23(Suppl 2):47-55. doi: 10.3851/IMP3245. Review.

Supplemental Content

Loading ...
Support Center